CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 40 enrolled
Drug / intervention
TAK-935 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02539134
NCT02539134Phase 1Completed
CompareCT.gov

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Escalating Multiple Doses of TAK-935 in Healthy Subjects

Takeda·interventional·Posted Sep 2, 2015·Updated Jul 12, 2017

In Brief

A Phase 1 clinical trial evaluating TAK-935 and Placebo for Epilepsy. Completed, enrolled 40 participants across 1 site.

Detailed Summary

The purpose of this study is to assess the safety, tolerability and pharmacokinetics (PK) of multiple rising doses of TAK-935 in healthy participants.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEpilepsy
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
20162017201820192020202120222023202420252026
First PostedSep 2, 2015
Enrollment StartSep 1, 2015
Primary CompletionApr 1, 2016
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 10.8 years ago

Interventions

TAK-935drug

TAK-935 oral solution

Placebodrug

TAK-935 placebo-matching oral solution